Рандомизированные контролируемые испытания у больных с сердечной недостаточностью в России после исследования TOPCAT: что нас ожидает впереди

1. Pitt B., Pfeffer M. A., Assmann S. F., Boineau R., Anand I. S., Claggett B. et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(l5):1383-92. doi:10.1056/NEJMoa1313731

2. Pfeffer M. A., Claggett B., Assmann S. F., Boineau R., Anand I. S., Clausell N. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT ) trial. Circulation. 2015;131(1): 34-42. doi:10.1161/CIRCULATI0NAHA.114.013255

3. Bristow M. R., Enciso J. S., Gersh B.J., Grady C., Rice M. M., Singh S. et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC Basic Transl Sci. 2016;1(3):180-9. doi:10.1016/ j.jacbts. 2016.03.001

4. de Denus S., O'Meara E., Desai A.S., Claggett B., Lewis E.F., Leclair G. et al. Spironolactone metabolites in TOPCAT - new insights into regional variation. N EnglJ Med. 2017;376 (17):1690 2. doi:10. 1056/NEJMc1612601

5. Ferreira J.P., Girerd N., Rossignol P., Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail. 2015;17(9):893-905. doi:10.1002/ejhf.326.

6. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.

7. Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017;18 (1):3-40 DOI: 10.18087/rhfj.2017.1.2346.